1. Home
  2. MICC vs CYTK Comparison

MICC vs CYTK Comparison

Compare MICC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MICC

The Magnum Ice Cream Company N.V. Ordinary Shares

N/A

Current Price

$14.18

Market Cap

9.0B

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$66.42

Market Cap

7.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MICC
CYTK
Founded
2025
1997
Country
Netherlands
United States
Employees
16571
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
7.6B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
MICC
CYTK
Price
$14.18
$66.42
Analyst Decision
Hold
Strong Buy
Analyst Count
1
19
Target Price
N/A
$89.26
AVG Volume (30 Days)
1.4M
1.5M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,368,000.00
Revenue This Year
$5.51
$7.37
Revenue Next Year
$4.17
$310.19
P/E Ratio
$28.55
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.96
$29.31
52 Week High
$19.93
$70.98

Technical Indicators

Market Signals
Indicator
MICC
CYTK
Relative Strength Index (RSI) 39.91 56.57
Support Level $14.06 $59.12
Resistance Level $15.94 $67.93
Average True Range (ATR) 0.28 2.12
MACD 0.03 0.13
Stochastic Oscillator 19.39 52.14

Price Performance

Historical Comparison
MICC
CYTK

About MICC The Magnum Ice Cream Company N.V. Ordinary Shares

The Magnum Ice Cream Co NV is a spinoff from Unilever, pure-play in manufacturing and selling a broad portfolio of ice-cream brands. TMICC ice-cream portfolio includes Magnum, Ben and Jerrys, Cornetto and the Heart brand. The company is organised into three geographic regions (i) Europe and ANZ, (ii) Americas, and (iii) AMEA.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: